Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

Bone Marrow Transplantation volume 50, pages 1150–1156 (2015)Cite this article

Subjects

Abstract

The source of hematopoietic stem cells (HSCs) for allogeneic transplantation has evolved over the last decades, from the sole use of unstimulated bone marrow (BM) to the use of G-CSF (filgrastim)-mobilized peripheral blood, G-CSF-primed BM (G-BM) and cord blood. G-CSF-mobilized PBSC has replaced BM as the most commonly used source of allogeneic stem cells. G-BM is a source of HSCs, with studies demonstrating the safety and feasibility of this strategy with the potential for reducing GvHD, while retaining the speed of engraftment. Although the G-BM had lost its use as the optimal source of stem cells, after the widespread use of haploidentical transplantation, their use has resurfaced in 2010. This source can still be used in today’s world of transplantation in aplastic anemia and other benign diseases, as well as in children donors. This study intends to review the evidence for this approach and whether this approach still has merit in the ever-evolving field of allogenic HSC transplantation. The merit of G-BM is its ability to offer speed of engraftment with reduced GvHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Donato M, Champlin R . Granulocyte colony-stimulating factor-primed bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 419–412.

    Article  CAS  PubMed  Google Scholar 

  2. Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2013.

  3. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014; 4: CD010189.

    Google Scholar 

  4. To LB, Haylock DN, Simmons PJ, Juttner CA . The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–2258.

    CAS  PubMed  Google Scholar 

  5. Richman CM, Weiner RS and, Yankee RA . Increasing in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031.

    CAS  PubMed  Google Scholar 

  6. Lormann HP, Schremal W, Fliedner TM, Heimpel H . Reaction of granulopoiesis to high doses cyclophosphamide therapy. Blut 1979; 38: 9–16.

    Article  Google Scholar 

  7. Stiff PJ, Murgo AJ, Wittes RF, De Risi MF, Clarkson BD . Quantification of peripheral blood colony forming unit-culture rise following chemotherapy- could leukocytaphereses relapse bone marrow for autologous transplantation? Transfusion 1983; 23: 500–503.

    Article  CAS  PubMed  Google Scholar 

  8. To LB, Haylock DN, Kimber RJ, Juttner CA . High Levels of circulating hemopoietic stem cells in very early remission from acute non-lymphoblastic leukemia and their collection; and cryopreservation. Br J Haematol 1984; 58: 399–410.

    Article  CAS  PubMed  Google Scholar 

  9. Bernard PH, Reiffers J, Verzon G, Sarrat A, Marit G, David B et al. Collection of circulating haemopoietic cells after chemotherapy in acute non-lymphocytic leukaemia. Br J Haematol 1985; 61: 577–578.

    Article  CAS  PubMed  Google Scholar 

  10. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442–447.

    CAS  PubMed  Google Scholar 

  11. Stoppa AM, Blaise D, Viens P, Baume D, Mannoni P, Novakovitch G et al. Phase I study of in vivo lenograstim (rHiG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 541–547.

    CAS  PubMed  Google Scholar 

  12. Hansen PB, Knudsen H, Gaarsdal E, Jensen L, Ralfkiaer E, Johnsen HE . Short- term in vivo priming of bone marrow haematopiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. Bone Marrow Transplant 1995; 16: 373–379.

    CAS  PubMed  Google Scholar 

  13. Lemoli RM, Tafuri A, Fortuna A, Petrucci MT, Ricciardi MR, Catani L et al. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997; 89: 1189–1196.

    CAS  PubMed  Google Scholar 

  14. Johansen HE, Hansen PB, Plesner T, Jensen L, Gaarsdal E, Andersen H et al. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant. 1992; 10: 229–234.

    Google Scholar 

  15. Martinez C, Urbano-Ispizua A, Rozman M, Rovira M, Marin P, Montfort N et al. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Bone Marrow Transplant 1999; 23: 15–19.

    Article  CAS  PubMed  Google Scholar 

  16. Janssen WE, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz JH et al. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens. Prog Clin Biol Res 1994; 389: 429–439.

    CAS  PubMed  Google Scholar 

  17. Knudsen LM, Hansen SW, Daugard G, Jarlbaek L, Agerbaek M, Jensen L et al. Comparison of rhG-CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumors. Eur J Haematol 1998; 61: 229–234.

    Article  CAS  PubMed  Google Scholar 

  18. Damiani D, Franin R, Silvestri F, Grimaz S, Infanti L, Geromin A et al. Randomized trial of autologous filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90: 36–42.

    CAS  PubMed  Google Scholar 

  19. Couban S, Messner HA, Andreou P, Egan B, Price S, Tinker L et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplantation. Biol Blood Marrow Transplant 2000; 6: 422–427.

    Article  CAS  PubMed  Google Scholar 

  20. Isola L, Seigliano E, Fruchtman S . Long-term follow-up after allogeneic granulocyte colony- stimulating factor—primed bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6: 428–433.

    Article  CAS  PubMed  Google Scholar 

  21. Serody JS, Sparks SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL et al. Comparison of granulocyte colony-stimulating factor (G-CSF)—mobilized peripheral blood progenitor cells and G-CSF— stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434–440.

    Article  CAS  PubMed  Google Scholar 

  22. Morton J, Hutchins C, Durrant S . Granulocyte-colony-stimulating factor (G-CSF)- primed allogeneic bone marrow: significant less graft-versus-host-disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186–3191.

    Article  CAS  PubMed  Google Scholar 

  23. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associatedwith a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.

    CAS  PubMed  Google Scholar 

  24. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O . Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548–551.

    Article  CAS  PubMed  Google Scholar 

  25. Couban S, Barnett M . The source of cells for allografting. Biol Blood Marrow Transplant 2003; 9: 669–673.

    Article  PubMed  Google Scholar 

  26. Chiang K-Y, Lamb L, Clark J, Worthington-White D, Rich I, Henslee-Downey PJ . Assessment of G-CSF stimulated BM hemopoietic stem cells in normal donors. Cytotherapy 2002; 4: 55–63.

    Article  CAS  PubMed  Google Scholar 

  27. Sun LX, Zhao YT, Chang YJ . Peripheral blood stem cell transplantation or bone marrow transplant in allogeneic settings: which should be chosen? Leuk Res 2012; 36: e116–e117.

    Article  PubMed  Google Scholar 

  28. Jun HX, Jun CY, Yu ZX . In vivo induction of T-cell hyporesposiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517–1524.

    CAS  PubMed  Google Scholar 

  29. Klangsinsirikul P, Russell NH . Peripheral blood stem harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dentritic cells. Exp Hematol 2002; 30: 495–501.

    Article  CAS  PubMed  Google Scholar 

  30. Hassan HT, Stockschlader M, Schleimer B, Kruger W, Zander AR . Comparison of the content and subpopulations of CD3 and CD34positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapherisis products from from healthy adult donors. Transpl Immunol 1996; 4: 319–323.

    Article  CAS  PubMed  Google Scholar 

  31. Shier LR, Schultz KR, Imren S, Regan J, Issekutz A, Sadek J et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant 2004; 10: 624–634.

    Article  CAS  PubMed  Google Scholar 

  32. Chang YJ, Zhao XY, Huo MR, Huang XJ . Expression profiles of adhesion molecules on naive T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl Immunol 2009; 21: 228–233.

    Article  CAS  PubMed  Google Scholar 

  33. Jun HX, Jun CY, Yu ZX . A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G CSFmobilized peripheral blood grafts. Haematologica 2005; 90: 715–716.

    PubMed  Google Scholar 

  34. Jun HX, Jun CY, Yu ZX . In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517–1524.

    CAS  PubMed  Google Scholar 

  35. Isola LM, Scigliano E, Skerrett D, Shank B, Ross V, Najfeld V et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997; 20: 1033–1037.

    Article  CAS  PubMed  Google Scholar 

  36. Ji SQ, Chen HR, Xun CQ, Wang HX, Pan SP, Xiao MH . The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft – versus-host disease in allogeneic bone marrow transplantation. Clin Transplant 2001; 15: 317–323.

    Article  CAS  PubMed  Google Scholar 

  37. Ji SQ, Chen HR, Wang HX, Yan HM, Pan Sp, Xun CQ . Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 261–267.

    Article  PubMed  Google Scholar 

  38. Ostronoff M, Ostronoff F, Souto Major P, Matias C, Calixto R, Sucupira A et al. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 729–733.

    Article  CAS  PubMed  Google Scholar 

  39. Elfenbein GJ, Sacktein R, Oblon DJ . Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow –derived stem cells? No!. Blood Cells Mol Dis 2004; 32: 106–111.

    Article  CAS  PubMed  Google Scholar 

  40. Chang YJ, Zhao XY, Huo MR, Huang XJ . Expression profile of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl Immunol 2009; 21: 228–233.

    Article  CAS  PubMed  Google Scholar 

  41. Couban S, Aljurf M, Lachance S, Walker I, Toze CL, Rubinger M et al. A Canadian Blood and Marrow Transplant Group (CBMTG) randomised trial comparing G-CSF mobilized peripheral blood versus G-CSF stimulated bone marrow in recipients of sibling allografts for hematologic malignancies. Blood 2013; 122: 709–739.

    Google Scholar 

  42. Ringdén O, Labopin M, Gorin N-C, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416–423.

    Article  PubMed  Google Scholar 

  43. Khoury HJ, Loberiza FR Jr, Ringden O, Barrett JA, Bolwell BJ, Cahn J-Y et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712–1716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Morris ES, MacDonald KPA, Kuns RD, Morris HM, Banovic T, Don ALJ et al. Induction of natural killer T cell–dependent alloreactivity by administration of granulocyte colony–stimulating factor after bone marrow transplantation. Nat Med 2009; 15: 436–441.

    Article  CAS  PubMed  Google Scholar 

  45. Bortin MM, Buckner CD . Major complications of marrow harvesting for transplantation. Exp Hematol 1983; 11: 916–921.

    CAS  PubMed  Google Scholar 

  46. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC et al. Marrow harvesting from normal donors. Blood 1984; 64: 630–634.

    CAS  PubMed  Google Scholar 

  47. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.

    CAS  PubMed  Google Scholar 

  48. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.

    Article  CAS  PubMed  Google Scholar 

  49. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  PubMed  Google Scholar 

  50. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873–880.

    Article  CAS  PubMed  Google Scholar 

  51. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.

    Article  CAS  PubMed  Google Scholar 

  52. Storek J, Dawson MA, Maloney DG . Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993–2994.

    CAS  PubMed  Google Scholar 

  53. Meuller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C et al. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sanguinis 2013; 104: 46–54.

    Article  Google Scholar 

  54. Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405–414.

    Article  PubMed  Google Scholar 

  55. Miflin G, Charley C, Stainer C, Anderson S, Hunter A, Russell N . Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996; 95: 345–348.

    Article  CAS  PubMed  Google Scholar 

  56. Kennedy GA, Morton J, Western R, Butler J, Daly J, Durrant S . Impact of stem cell donation modality on normal donor quality of life: a prospective randomized study. Bone Marrow Transplant 2003; 31: 1033–1035.

    Article  CAS  PubMed  Google Scholar 

  57. Heldal D, Brinch L, Tjonnfjord G, Solheim BG, Egeland G, Albrechtsen D et al. Donation of stem cells from blood or bone marrow: results of randomized study of safety and complaints. Bone Marrow Transplant 2002; 29: 479–486.

    Article  CAS  PubMed  Google Scholar 

  58. Gutierrez-Delgado F, Bensinger W . Safety of granulocyte colony stimulating factor in normal donors. Curr Opin Hematol 2001; 8: 155–160.

    Article  CAS  PubMed  Google Scholar 

  59. Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A et al. Health-related QoL of bone marrow versus PBSC donors: a prespecified subgroup analysis from a phase III RCT—BMTCTN protocol 0201. Biol Blood Marrow Transplant 2014; 20: 118–127.

    Article  PubMed  Google Scholar 

  60. Billen A, Madrigal JA, Strydom A, Szydlo RM, Switzer GE et al. Predonation health-related quality of life scores predict time to recovery in hematopoietic stem cell donors. Biol Blood Marrow Transplant 2015; 21: 350–356.

    Article  PubMed  Google Scholar 

  61. Wang Y, Liu DH, Liu KY, Lang-Ping X, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978–985.

    Article  PubMed  Google Scholar 

  62. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.

    Article  CAS  PubMed  Google Scholar 

  63. Chang YJ, Huang XJ . Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. Clin Transplant 2011; 25: 13–23.

    Article  CAS  PubMed  Google Scholar 

  64. Heimfeld S . Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? Leukemia 2003; 17: 856–858.

    Article  CAS  PubMed  Google Scholar 

  65. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony stimulating factor- mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen- identical sibling transplantation. Blood 2001; 98: 3221–3227.

    Article  CAS  PubMed  Google Scholar 

  66. Bensinger WI, Martin PJ, Storer B, Clift R, Forman Sj, Negrin R et al. Transplantation of Bone Marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologica cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  67. Novotny JR, Rosenthal C, Elmaagacli AH, Durig J, Beelen DW, Duhrsen U . Disease- or therapy- bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation. Eur J Haematol 2004; 73: 1–9.

    Article  CAS  PubMed  Google Scholar 

  68. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem –cell compared with bone marrow transplantation in the management of hematological malignancies: an individual patient data meta- analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Article  Google Scholar 

  69. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone, marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288–4290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Carmitta B et al. Comparison of outcomes after transplantation of G-CSF–stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant 2011; 17: 1018–1024.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Allogeneic Bone Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

    U Deotare, G Al-Dawsari & J H Lipton

  2. Department of Medicine, Dalhousie University, Halifax, NS, Canada

    S Couban

Authors
  1. U Deotare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Al-Dawsari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Couban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J H Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J H Lipton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deotare, U., Al-Dawsari, G., Couban, S. et al. G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant 50, 1150–1156 (2015). https://doi.org/10.1038/bmt.2015.80

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.80

This article is cited by

Search

Advanced search

Quick links